119 related articles for article (PubMed ID: 24779514)
1. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
2. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
3. Identification of natural product-based effective inhibitors of spleen tyrosine kinase (SYK) through virtual screening and molecular dynamics simulation approaches.
Ali T; Anjum F; Choudhury A; Shafie A; Ashour AA; Almalki A; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2024 Apr; 42(7):3459-3471. PubMed ID: 37261484
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors.
Lee SJ; Choi JS; Bong SM; Hwang HJ; Lee J; Song HJ; Lee J; Kim JH; Koh JS; Lee BI
Mol Cells; 2018 Jun; 41(6):545-552. PubMed ID: 29890824
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors.
Grimster NP; Gingipalli L; Balazs A; Barlaam B; Boiko S; Boyd S; Dry H; Goldberg FW; Ikeda T; Johnson T; Kawatkar S; Kemmitt P; Lamont S; Lorthioir O; Mfuh A; Patel J; Pike A; Read J; Romero R; Sarkar U; Sha L; Simpson I; Song K; Su Q; Wang H; Watson D; Wu A; Zehnder TE; Zheng X; Li S; Dong Z; Yang D; Song Y; Wang P; Liu X; Dowling JE; Edmondson SD
Bioorg Med Chem Lett; 2023 Jul; 91():129352. PubMed ID: 37270074
[TBL] [Abstract][Full Text] [Related]
6. Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK).
Wang Z; Qu S; Yuan J; Tian W; Xu J; Tao R; Sun S; Lu T; Tang W; Zhu Y
Bioorg Med Chem; 2023 Dec; 96():117514. PubMed ID: 37984216
[TBL] [Abstract][Full Text] [Related]
7. Exploring molecular interactions of potential inhibitors against the spleen tyrosine kinase implicated in autoimmune disorders via virtual screening and molecular dynamics simulations.
Samanta S; Sk MF; Koirala S; Kar P
SAR QSAR Environ Res; 2023 Oct; ():1-29. PubMed ID: 37881946
[TBL] [Abstract][Full Text] [Related]
8. Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Huang Y; Li Y; Dong G; Zhang W; Liu N; Sheng C
Arch Pharm (Weinheim); 2018 Jun; ():. PubMed ID: 29952085
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase.
Tung MC; Tsai KC; Fung KM; Don MJ; Tseng TS
RSC Adv; 2021 Jan; 11(4):2453-2461. PubMed ID: 35424194
[TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.
Rolf MG; Curwen JO; Veldman-Jones M; Eberlein C; Wang J; Harmer A; Hellawell CJ; Braddock M
Pharmacol Res Perspect; 2015 Oct; 3(5):e00175. PubMed ID: 26516587
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.
Jia H; Deng W; Hao B; Cai M; Guo D; Cai Y; Dai X; Wu Z; He W; Wang J; Wang G; Xia S; Li N; Su W; Dai G
ACS Med Chem Lett; 2024 May; 15(5):595-601. PubMed ID: 38746892
[TBL] [Abstract][Full Text] [Related]
12. Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.
Risch Z; Kaffenberger BH; Chung CG; Samorodnitsky E; Hoskins EL; Dao T; Smith A; Wall SA; Brammer J; Reeser JW; Wing MR; Hopkins JF; Albacker LA; Abruzzo LV; Eisele CD; Freud AG; Roychowdhury S; Walsh KE
Haematologica; 2024 May; ():. PubMed ID: 38813710
[TBL] [Abstract][Full Text] [Related]
13. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Sharman J; Hawkins M; Kolibaba K; Boxer M; Klein L; Wu M; Hu J; Abella S; Yasenchak C
Blood; 2015 Apr; 125(15):2336-43. PubMed ID: 25696919
[TBL] [Abstract][Full Text] [Related]
14. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
[TBL] [Abstract][Full Text] [Related]
15. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
16. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib.
Sharman J; Di Paolo J
Ther Adv Hematol; 2016 Jun; 7(3):157-70. PubMed ID: 27247756
[TBL] [Abstract][Full Text] [Related]
17. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
[TBL] [Abstract][Full Text] [Related]
18. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis.
Clarke AS; Rousseau E; Wang K; Kim JY; Murray BP; Bannister R; Matzkies F; Currie KS; Di Paolo JA
Thromb Res; 2018 Oct; 170():109-118. PubMed ID: 30172129
[TBL] [Abstract][Full Text] [Related]
19. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
Ramanathan S; Di Paolo JA; Jin F; Shao L; Sharma S; Robeson M; Kearney BP
Clin Drug Investig; 2017 Feb; 37(2):195-205. PubMed ID: 27785737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
